{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:14Z","timestamp":1792784894670,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Permanente Medical Group","id":[{"id":"https:\/\/ror.org\/05dsgrz38","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01151-2","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:21:41Z","timestamp":1791973301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fracture risk and fracture risk factor assessment among men at prostate cancer diagnosis"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3737-6667","authenticated-orcid":false,"given":"Michael J.","family":"Shulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4390-1445","authenticated-orcid":false,"given":"Jeanne A.","family":"Darbinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Harzstark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7159-0648","authenticated-orcid":false,"given":"Joan C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.juro.2017.09.103","volume":"199","author":"KA Houston","year":"2018","unstructured":"Houston KA, King J, Li J, Jemal A. Trends in prostate cancer incidence rates and prevalence of prostate-specific antigen screening by socioeconomic status and regions in the United States, 2004 to 2013. J Urol. 2018;199:676\u201382.","journal-title":"J Urol"},{"key":"1151_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000040","volume":"1","author":"A Liede","year":"2016","unstructured":"Liede A, Hallett DC, Hope K, Graham A, Arellano J, Shahinian VB. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open. 2016;1:e000040.","journal-title":"ESMO Open"},{"key":"1151_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547\u201358.","journal-title":"N Engl J Med"},{"key":"1151_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154\u201364.","journal-title":"N Engl J Med"},{"key":"1151_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pds.2258","volume":"21","author":"JL Beebe-Dimmer","year":"2012","unstructured":"Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, et al. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf. 2012;21:70\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1151_CR6","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s00198-015-3135-9","volume":"26","author":"CT Wu","year":"2015","unstructured":"Wu CT, Yang YH, Chen PC, Chen MF, Chen WC. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int. 2015;26:2281\u201390.","journal-title":"Osteoporos Int"},{"key":"1151_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.652979","volume":"12","author":"CC Wu","year":"2021","unstructured":"Wu CC, Chen PY, Wang SW, Tsai MH, Wang YCL, Tai CL, et al. Risk of fracture during androgen deprivation therapy among patients with prostate cancer: a systematic review and meta-analysis of cohort studies. Front Pharmacol. 2021;12:652979.","journal-title":"Front Pharmacol"},{"key":"1151_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/phar.2168","volume":"38","author":"C Nguyen","year":"2018","unstructured":"Nguyen C, Lairson DR, Swartz MD, Du XL. Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer. Pharmacotherapy. 2018;38:999\u20131009.","journal-title":"Pharmacotherapy"},{"key":"1151_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","volume":"175","author":"MR Smith","year":"2006","unstructured":"Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136\u20139.","journal-title":"J Urol"},{"key":"1151_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","volume":"111","author":"YH Shao","year":"2013","unstructured":"Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013;111:745\u201352.","journal-title":"BJU Int"},{"key":"1151_CR11","doi-asserted-by":"publisher","first-page":"75646","DOI":"10.18632\/oncotarget.17980","volume":"8","author":"L Cianferotti","year":"2017","unstructured":"Cianferotti L, Bertoldo F, Carini M, Kanis JA, Lapini A, Longo N, et al. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the International Osteoporosis Foundation. Oncotarget. 2017;8:75646\u201363.","journal-title":"Oncotarget"},{"key":"1151_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1046\/j.1464-410X.2003.04471.x","volume":"92","author":"SA Hussain","year":"2003","unstructured":"Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual-energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003;92:690\u20134.","journal-title":"BJU Int"},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12020-015-0536-7","volume":"50","author":"AC Lassemillante","year":"2015","unstructured":"Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine. 2015;50:344\u201354.","journal-title":"Endocrine"},{"key":"1151_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.juro.2011.03.149","volume":"186","author":"R Mistry","year":"2011","unstructured":"Mistry R, Hughes D, Wadhwa V, Parr N. Lateral spine radiographs before androgen deprivation treatment detect a high incidence of undiagnosed vertebral fragility fractures in men with advanced prostate cancer. J Urol. 2011;186:474\u201380.","journal-title":"J Urol"},{"key":"1151_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00198-018-4722-3","volume":"30","author":"M Wallander","year":"2019","unstructured":"Wallander M, Axelsson KF, Lundh D, Lorentzon M. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures: a study from the fractures and fall injuries in the elderly cohort (FRAILCO). Osteoporos Int. 2019;30:115\u201325.","journal-title":"Osteoporos Int"},{"key":"1151_CR16","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/jbmr.405","volume":"26","author":"LJ Melton 3rd","year":"2011","unstructured":"Melton LJ 3rd, Lieber MM, Atkinson EJ, Achenbach SJ, Zincke H, et al. Fracture risk in men with prostate cancer: a population-based study. J Bone Min Res. 2011;26:1808\u201315.","journal-title":"J Bone Min Res"},{"key":"1151_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","volume":"19","author":"B Dawson-Hughes","year":"2008","unstructured":"Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449\u201358.","journal-title":"Osteoporos Int"},{"key":"1151_CR18","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/jbmr.4417","volume":"36","author":"SE Noel","year":"2021","unstructured":"Noel SE, Santos MP, Wright NC. Racial and ethnic disparities in bone health and outcomes in the United States. J Bone Min Res. 2021;36:1881\u2013905.","journal-title":"J Bone Min Res"},{"key":"1151_CR19","unstructured":"Home | FRAXplus\u00ae [Available from: https:\/\/www.fraxplus.org\/."},{"key":"1151_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"U. S. Preventive Services Task Force","year":"2011","unstructured":"U. S. Preventive Services Task ForceScreening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154:356\u201364.","journal-title":"Ann Intern Med"},{"key":"1151_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00198-009-0984-0","volume":"21","author":"RA Adler","year":"2010","unstructured":"Adler RA, Hastings FW, Petkov VI. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int. 2010;21:647\u201353.","journal-title":"Osteoporos Int"},{"key":"1151_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1078155211402105","volume":"18","author":"V Dhanapal","year":"2012","unstructured":"Dhanapal V, Reeves DJ. Bone health management in prostate cancer patients receiving androgen deprivation therapy. J Oncol Pharm Pract. 2012;18:84\u201390.","journal-title":"J Oncol Pharm Pract"},{"key":"1151_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.urology.2013.12.071","volume":"84","author":"H James 3rd","year":"2014","unstructured":"James H 3rd, Aleksic I, Bienz MN, Pieczonka C, Iannotta P, et al. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy. Urology. 2014;84:164\u20138.","journal-title":"Urology"},{"key":"1151_CR24","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/924595","volume":"2011","author":"K Neubecker","year":"2011","unstructured":"Neubecker K, Adams-Huet B, Farukhi IM, Delapena RC, Gruntmanis U. Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. J Osteoporos. 2011;2011:924595.","journal-title":"J Osteoporos"},{"key":"1151_CR25","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.juro.2010.02.022","volume":"183","author":"PJ Saylor","year":"2010","unstructured":"Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010;183:2200\u20135.","journal-title":"J Urol"},{"key":"1151_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5152\/tud.2019.11736","volume":"45","author":"A Sharma","year":"2019","unstructured":"Sharma A, Sinha RJ, Singh V, Garg G, Agarwal S, Pandey S. Implications of the fracture risk assessment algorithm for the assessment and improvement of bone health in patients with prostate cancer: a comprehensive review. Turk J Urol. 2019;45:245\u201353.","journal-title":"Turk J Urol"},{"key":"1151_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jocd.2016.04.011","volume":"19","author":"AM McDonald","year":"2016","unstructured":"McDonald AM, Jones JA, Cardan RA, Saag KS, Mayhew DL, Fiveash JB. Combining computed tomography-based bone density assessment with FRAX screening in men with prostate cancer. J Clin Densitom. 2016;19:430\u20135.","journal-title":"J Clin Densitom"},{"key":"1151_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3109\/0284186X.2012.762995","volume":"52","author":"R Valery","year":"2013","unstructured":"Valery R, Mendenhall NP, Nichols RC Jr., Henderson R, Morris CG, Su Z, et al. Hip fractures and pain following proton therapy for the management of prostate cancer. Acta Oncol. 2013;52:486\u201391.","journal-title":"Acta Oncol"},{"key":"1151_CR29","doi-asserted-by":"crossref","unstructured":"Nicholson WK, Silverstein M, et al.U. S. Preventive Services Task Force Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2025;333:498\u2013508.","DOI":"10.1001\/jama.2024.27154"},{"key":"1151_CR30","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049\u2013102.","journal-title":"Osteoporos Int"},{"key":"1151_CR31","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR32","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.jocd.2023.101435","volume":"27","author":"C Shuhart","year":"2024","unstructured":"Shuhart C, Cheung A, Gill R, Gani L, Goel H, Szalat A. Executive Summary of the 2023 Adult Position Development Conference of the International Society for Clinical Densitometry: DXA reporting, follow-up BMD testing and trabecular bone score application and reporting. J Clin Densitom. 2024;27:101435.","journal-title":"J Clin Densitom"},{"key":"1151_CR33","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, Yi A, Bitting R, et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines: Prostate Cancer Version 2.2026. NCCN\u00ae; 2025."},{"key":"1151_CR34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jbmr\/zjaf012","volume":"40","author":"RK Jain","year":"2025","unstructured":"Jain RK, Liu JY, Grant RW, Haider S, Huang ES, Laiteerapong N, et al. Biases in the performance of FRAX without BMD in predicting fracture risk in a multiethnic population with diabetes: the Diabetes and Aging Study. J Bone Min Res. 2025;40:478\u201391.","journal-title":"J Bone Min Res"},{"key":"1151_CR35","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737\u201349.","journal-title":"N Engl J Med"},{"key":"1151_CR36","first-page":"245","volume":"67","author":"MK Buyyounouski","year":"2017","unstructured":"Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer's eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:245\u201353.","journal-title":"CA Cancer J Clin"},{"key":"1151_CR37","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00198-024-07162-w","volume":"35","author":"JA Kanis","year":"2024","unstructured":"Kanis JA, Harvey NC, Lorentzon M, Liu E, Schini M, Abrahamsen B, et al. Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk. Osteoporos Int. 2024;35:1487\u201396.","journal-title":"Osteoporos Int"},{"key":"1151_CR38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jbmr\/zjae107","volume":"39","author":"B Dawson-Hughes","year":"2024","unstructured":"Dawson-Hughes B, Cosman F, McClung M. Letter to the editor regarding \u201cThe American Society for Bone and Mineral Research Task Force on clinical algorithms for fracture risk report. J Bone Min Res. 2024;39:1371\u20132.","journal-title":"J Bone Min Res"},{"key":"1151_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/jbmr\/zjae048","volume":"39","author":"SM Burnett-Bowie","year":"2024","unstructured":"Burnett-Bowie SM, Wright NC, Yu EW, Langsetmo L, Yearwood GMH, Crandall CJ, et al. The American Society for Bone and Mineral Research Task Force on clinical algorithms for fracture risk report. J Bone Min Res. 2024;39:517\u201330.","journal-title":"J Bone Min Res"},{"key":"1151_CR40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1056\/NEJMms2004740","volume":"383","author":"DA Vyas","year":"2020","unstructured":"Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight - reconsidering the use of race correction in clinical algorithms. N Engl J Med. 2020;383:874\u201382.","journal-title":"N Engl J Med"},{"key":"1151_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","volume":"19","author":"AN Tosteson","year":"2008","unstructured":"Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437\u201347.","journal-title":"Osteoporos Int"},{"key":"1151_CR42","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/jbmr.4793","volume":"38","author":"C Ye","year":"2023","unstructured":"Ye C, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, et al. Performance of FRAX in men with prostate cancer: a registry-based cohort study. J Bone Min Res. 2023;38:659\u201364.","journal-title":"J Bone Min Res"},{"key":"1151_CR43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.juro.2011.10.136","volume":"187","author":"AK Morgans","year":"2012","unstructured":"Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2012;187:889\u201393.","journal-title":"J Urol"},{"key":"1151_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/UPJ.0000000000000473","volume":"11","author":"ED Crawford","year":"2024","unstructured":"Crawford ED, Garnick MB, Eckel RH, Miner MM, Freedland SJ, Pachynski RK, et al. A proposal for the comprehensive care of men on androgen deprivation therapy: recommendations from the multidisciplinary Prostate Cancer 360 Working Group. Urol Pract. 2024;11:18\u201329.","journal-title":"Urol Pract"},{"key":"1151_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399\u2013428.","journal-title":"Osteoporos Int"},{"key":"1151_CR46","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.20.00434","volume":"38","author":"A Dalla Volta","year":"2020","unstructured":"Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, et al. Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol. 2020;38:3363\u20136.","journal-title":"J Clin Oncol"},{"key":"1151_CR47","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/jbmr.3538","volume":"33","author":"WD Leslie","year":"2018","unstructured":"Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD registry. J Bone Min Res. 2018;33:1923\u201330.","journal-title":"J Bone Min Res"},{"key":"1151_CR48","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00198-018-4650-2","volume":"29","author":"SL Ferrari","year":"2018","unstructured":"Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018;29:2585\u201396.","journal-title":"Osteoporos Int"},{"key":"1151_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.37765\/ajmc.2024.89515","volume":"30","author":"JC Lo","year":"2024","unstructured":"Lo JC, Chandra M, Yang W, Thompson N, Lee C, Ramaswamy M, et al. Challenges of fracture risk assessment in Asian and Black women. Am J Manag Care. 2024;30:140\u20134.","journal-title":"Am J Manag Care"},{"key":"1151_CR50","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468\u201389.","journal-title":"Osteoporos Int"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01151-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:21:43Z","timestamp":1791973303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01151-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":50,"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01151-2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Shulman, Jeanne Darbinian, Malini Chandra, Andrea Harzstark, and Joan Lo have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}